Pain, Side Effects, and Abortion Experience Among People Seeking Abortion Care in the Second Trimester

Ilana G. Dzuba,1 Sruthi Chandrasekaran,2,* Laura Fix,2 Kelly Blanchard,2 and Erin King3

Abstract

Background: There is limited documentation about pain and side effects associated with dilation and evacuation (D&E) abortion, yet, pain and side effects are important factors that can affect a client’s abortion experience. In 2016, Hope Clinic for Women, an independent abortion clinic in Illinois, altered its cervical preparation protocols before D&E to reduce the total time of the abortion process and improve the client experience. This analysis addresses the gap in data on client experience of abortion in the later second trimester by evaluating pain, side effects, and acceptability by gestational age.

Methods: Abortion clients obtaining services at the clinic between March 2017 and June 2018 were eligible to participate if they had viable singleton pregnancies of 16–23.6 weeks’ gestation, spoke English, and were at least 18 years old. Eligible participants completed a two-part survey about their abortion experience.

Results: We found that respondents seeking abortion care at later gestations in the second trimester were more likely to report pain during their abortions. We did not find any association between side effects and gestational age.

Conclusion: Although most respondents were prepared for the pain they experienced, some reported experiencing more pain than they expected, and more effective pain relief was commonly reported as a way to improve the service. More research on patient experiences of later abortion is needed, particularly on experiences of pain and options for pain management.

Keywords: second-trimester abortion; pain; side effects; abortion experience; gestational age; secondary analysis

Introduction

Approximately 5.4% of facility-based abortion procedures in the United States in 2017 were performed among people seeking care with pregnancies at 16 or more weeks of gestation.1 Dilation and evacuation (D&E) is the method most commonly used in this country for mid to late second-trimester abortion and is very safe and effective.2 Achieving adequate cervical dilation is an important factor in avoiding potential complications with the procedure, such as hemorrhage and cervical laceration.3,4

1Consultant, New York, NY, USA.
2Ibis Reproductive Health, Cambridge, Massachusetts, USA.
3Hope Clinic for Women, Granite City, Illinois, USA.

*Address correspondence to: Sruthi Chandrasekaran, MSc, MA, Ibis Reproductive Health, 2067 Massachusetts Avenue, Suite 320, Cambridge, MA 02144, USA, E-mail: schandrasekaran@ibisreproductivehealth.org

© Ilana G. Dzuba et al., 2022; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License [CC-BY] (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

533
In 2016, Hope Clinic for Women, an independent abortion clinic in Illinois, altered its cervical preparation protocols before D&E to reduce the total time of the abortion process and improve the client experience.5–12

For pregnancies 16–17.6 weeks of gestation, osmotic dilators were discontinued and replaced with a 400 µg misoprostol (a widely available, heat stable, inexpensive E1 prostaglandin analog) dose 120 minutes before D&E, which studies show that clients generally prefer because of discomfort from dilator placement and shorter procedure duration.10,12,13 despite the greater likelihood of need for additional mechanical dilation.14–16

For pregnancies 21–23.6 weeks, mifepristone 200 mg (an antiprogesterin) was added as an adjunct to osmotic dilators on day 1, which providers report may make D&E procedures easier.11 On day 2, if dilation was adequate, misoprostol 400 µg was given 0–180 minutes before D&E. If dilation was determined to be insufficient by the provider, a second set of osmotic dilators were administered and the D&E was completed on day 3.

The protocol for pregnancies 18–20.6 weeks did not change—osmotic dilators are placed day 1, and on day 2, the D&E procedure was completed 0–180 minutes after misoprostol 400 µg.

These protocols are in line with the Society of Family Planning’s recommendations for cervical preparation before second trimester abortion up to 24 weeks gestational age.17,18 Intrafetal or intra-amniotic injection of 500 µg to 1.5 mg of digoxin was administered to everyone with pregnancies of 18 weeks and more.

There is limited documentation about pain and side effects associated with D&E abortion, yet, pain and side effects are important factors that can affect a client’s abortion experience.19,20 People who undergo D&E procedures report pain with dilator insertion, cervical dilation, injections to administer paracervical block and digoxin, uterine contractions, and postprocedure recovery.9,11,13,15,16 Digoxin is associated with vomiting21 and common side effects of misoprostol, if used for cervical preparation, include gastrointestinal upset as well as fever and chills. Misoprostol-associated side effects are transient and can be managed with gastrointestinal treatments such as antiemetics and anti diarrheals. Pain and side effect management, therefore, is a meaningful component of quality of care.22

Currently, there is no standardized approach nor clear recommendations for pain management during later abortion procedures.23 Given the limited data, Hope Clinic aimed to reduce overall pain and improve client experience by reducing the need for a second set of osmotic dilators.5

At Hope Clinic, a combination of preoperative oral analgesia with ibuprofen, anxiolysis with alprazolam, and intraoperative moderate sedation with fentanyl and versed was used for pain management during the D&E procedure. Oral analgesia with ibuprofen alone was administered for osmotic dilator insertion. Patients were given the oral analgesia medications such as ibuprofen and an acetaminophen combination with opioid at discharge on day 1 for self-administered use throughout their abortion process outside of the facility.

Other intravenous or intramuscular analgesia medications such as ketorolac and antiemetic medications such as ondansetron were available as needed for in-facility side effect management. Verbal anesthesia, heat, and uterine massage were also used for pain management. The pain management strategies in use at Hope Clinic reflect Society of Family Planning recommendations for using multiple interventions to address pain and improve patient experience.24 Pain and side effect management did not change with the altered cervical preparation protocol.

The D&E procedure is used across a broad gestational age range in the second trimester, but client experiences with pain and side effects may vary within that range based on the duration of the pregnancy. This analysis attempts to address the information gap in client experience of abortion in the later second trimester by analyzing data on pain, side effects, and acceptability by gestational age. A better understanding of client experiences among different gestational age cohorts will highlight potential ways to offer a higher quality and client-centered approach to abortion care.

Materials and Methods
We conducted an analysis on pain, acceptability, and side effects using data collected in a cross-sectional self-administered survey of later abortion clients at Hope Clinic with pregnancies of 16–23.6 weeks to compare the experiences of people who underwent original and modified cervical preparation protocols before D&E procedures. This article explores self-reported pain, side effects, and acceptability of the D&E procedure by gestational age group (16–17.6, 18–20.6, 21–23.6 weeks). The study was approved by Allendale Institutional Review Board.
Abortion clients obtaining services at the clinic between March 2017 and June 2018 were eligible to participate if they had viable singleton pregnancies of 16–23.6 weeks’ gestation, spoke English, and were at least 18 years old. Clinic staff did not recruit clients in emotional distress or those reporting safety concerns.

Clients learned about the study from a printed information sheet and/or verbally from clinic staff after undergoing abdominal ultrasound to confirm intrauterine pregnancy and estimate gestational age before initiating their abortions. Those interested in participating were given a packet with study information and informed consent procedures, a paper version of the self-administered, structured anonymous survey, and instructions on how to respond to the survey online (Qualtrics, Provo, UT) with a unique personalized link on a tablet at the clinic or on a personal device. Participants could instead opt to complete the paper survey and return in a preaddressed and stamped envelope.

Clients consented to participating in the study before proceeding to the survey questions. Those respondents who opted to use a paper survey could submit the completed survey to clinic staff in-person or in a self-addressed stamped envelope included in the packet.

The survey was completed in two sections. Respondents filled out the first section of 37 questions, including demographic information, before initiating their abortion procedures. Participants responded to an additional 32 questions postprocedure about the experience with the abortion procedure, including pain, side effects, and acceptability, as well as about clinic interactions. Participants who completed the first part of the survey received a $5 gift card and those who completed the remainder of the survey received an additional $20 gift card. Participants who completed the entire survey were entered into a raffle for one additional $100 gift card. The data used for this analysis were from the postprocedure portion of the survey.

Respondents rated the pain they experienced at different moments of the abortion process: cervical preparation in the clinic on day 1, cervical preparation after leaving the clinic on day 1, cervical preparation in the clinic on day 2 (if applicable), cervical preparation after leaving the clinic on day 2 (if applicable), digoxin administration on procedure day (if applicable), and the overall abortion process. They selected a number from 1 (no pain) to 10 (worst pain possible) on a visual analog pain scale, with corresponding circles of increasing size, that best reflected their pain.

Respondents also classified their perceptions about actual versus expected pain, actual versus expected side effects, actual versus expected reaction to abortion experience, the overall abortion experience, and care received at the clinic by Likert scales, and they were invited to offer recommendations to improve the abortion process.

For this analysis, we grouped all data by gestational age cohort (16–17.6, 18–20.6, and 21 weeks and beyond), regardless of cervical preparation protocol used. Data were analyzed with SPSS 20 (IBM, Armonk, NY), with $p<0.05$ considered significant. We used Pearson’s chi square and Fisher’s exact test as appropriate to evaluate group differences for outcomes based on categorical variables, the Kruskal-Wallis nonparametric test for multiple comparisons, and the Dunn test with Bonferroni correction as appropriate for post hoc adjusted pairwise comparisons.

**Results**

A total of 161 participants enrolled in the study. Two participants were excluded due to ineligibility: one was pregnant with a multiple gestation and another decided not to continue with the abortion procedure. Two additional were enrolled but eligibility details were unavailable and hence were excluded. Fifty-five (38.5%) of the 143 included respondents who initiated a survey did not return to the survey postprocedure. A total of 88 respondents who responded to the postprocedure survey portion were included in this analysis: 22 with pregnancies of 16–17.6 weeks, 42 with pregnancies of 18–20.6 weeks, and 24 with pregnancies 21–23.6 weeks (Figure 1).

Enrolled participants ranged from 18 to 42 years old; median pregnancy duration was 19 (interquartile range 17–21) weeks. Respondents identified primarily as black or African American (60.0%), followed by white (30.6%), Asian/Native Hawaiian or other Pacific Islander (2.4%), or other/mixed race (7.1%). No one in the sample identified ethnically as Hispanic, Latin, or Spanish, while 6.0% reported other ethnicity without specifying. Participants with pregnancies 21–23.6 weeks were more likely to have private insurance than those with pregnancies of <21 weeks. They were also more likely to be pregnant for the first time and be nulliparous. Table 1 shows the demographic characteristics of the surveyed population by gestational age.
cohort. The respondents who completed the entire survey were not sociodemographically different from those who responded to the first portion of the survey only (data not shown).

Pain
Nearly all (94.2%) respondents reported pain at some point during the abortion process, regardless of gestational age. Pain differed by gestational age after day 1, on day 2, after day 2, and overall. All respondents in the 21–23.6 weeks group reported pain on day 2, after day 2, and overall (Table 2).

Median pain scores among the total sample did not exceed 5 (out of 10) at any of the time points during the abortion that were asked about on the survey. However, when disaggregated by gestational age, a median pain score of 7 was assessed in the 18.0- to 20.6-week group for cervical preparation in clinic on day 1 and in the 21- to 23.6-week cohort for cervical preparation after leaving the clinic on day 2. After day 1, the median pain score was significantly higher in the 18- to 20.6-week group versus 16- to 17.6-week group (5 vs. 3, \( p = 0.002 \)) and after day 2, the median pain score was significantly higher in the 21- to 23.6-week group than in the 16- to 17.6-week group (7 vs. 2, \( p = 0.005 \)) and the 18- to 20.6-week group (7 vs. 4, \( p = 0.04 \)) (Table 2).

When asked to qualitatively rate their pain, most participants reported moderate (47%) or severe (20%) overall pain and discomfort during the abortion procedure, with 7% reporting extreme pain and discomfort and 12% reporting no pain and discomfort. Characterization of pain in this way did not vary by gestational age group (Fig. 2).

Respondents most commonly reported that the pain experienced was less than or same as expected, however, more than one-quarter of the sample reported that it exceeded expectations. When broken down by gestational age group, it held that participants primarily felt that the pain experienced was less than what they expected (Table 2).

Side effects
Nearly all (89%) respondents reported experiencing at least one side effect from the overall abortion experience, most commonly cramping (74%) and bleeding (65%). Approximately 11% of respondents reported no side effects (Fig. 3). Most participants reported that the side effects experienced were less than or the same as expected; approximately one-fifth reported they were more than expected. Reporting of side effects did not differ by gestational age (Table 3).

Acceptability
Respondents' assessments of their overall abortion experience were mostly positive. All respondents in the
Table 1. Demographic Characteristics of Respondents by Gestational Age (Weeks)

| Characteristic                              | 16–17.6   | 18–20.6   | ≥21       | Total     | \(p^a\) |
|---------------------------------------------|-----------|-----------|-----------|-----------|---------|
| **Gestational age**                         |           |           |           |           |         |
| Median Gestational age in weeks (IQR)      | 16 (16–17) | 19 (18–20) | 23 (22–23) | 19 (17–21) | <0.001  |
| **Age**                                     |           |           |           |           |         |
| Median age in years (IQR)                  | 26 (22–29) | 26 (22–31.5) | 24.5 (21–29) | 25 (22–30) | 0.64    |
| **Race, % (n)**                             |           |           |           |           |         |
| Black or African American                   | 68.2 (15) | 66.7 (26) | 41.7 (10) | 60.0 (51) |         |
| White                                       | 27.3 (6)  | 28.2 (11) | 37.5 (9)  | 30.6 (26) |         |
| Other                                       | 4.5 (1)   | 5.1 (2)   | 12.5 (3)  | 7.1 (6)   |         |
| **Ethnicity, % (n)**                        |           |           |           |           |         |
| Non-Hispanic                                | 95.5 (21) | 92.1 (35) | 95.8 (23) | 94.0 (79) |         |
| Other (nonspecified)                        | 4.5 (1)   | 7.9 (3)   | 4.2 (1)   | 6.0 (5)   |         |
| **Highest level of education, % (n)**       |           |           |           |           |         |
| Some or all of high school                  | 72.7 (16) | 84.6 (33) | 54.2 (13) | 72.9 (62) | 0.11    |
| Associate/Bachelor's Degree                 | 22.7 (5)  | 12.8 (5)  | 33.3 (8)  | 21.2 (18) |         |
| Master's Degree/Other                       | 4.5 (1)   | 2.6 (1)   | 12.5 (3)  | 5.9 (5)   |         |
| **Household income, % (n)**                 |           |           |           |           |         |
| Less than $15,000                            | 60.0 (12) | 54.5 (18) | 34.8 (8)  | 50.0 (38) | 0.08    |
| $15,000–$34,999                             | 40.0 (8)  | 36.4 (12) | 34.8 (8)  | 36.8 (28) |         |
| $35,000–$49,999                             | 0 (0)     | 6.1 (2)   | 8.7 (2)   | 5.3 (4)   |         |
| $50,000 and over                            | 0 (0)     | 3.0 (1)   | 21.7 (5)  | 7.9 (6)   |         |
| **Health insurance, % (n)\(^b\)**          |           |           |           |           |         |
| Private                                     | 13.6 (3)  | 7.5 (3)   | 45.8 (11) | 19.8 (17) | 0.001   |
| Medicaid                                    | 50.0 (11) | 52.5 (21) | 29.2 (7)  | 45.3 (39) | 0.17    |
| Medicare                                    | 9.1 (2)   | 2.5 (1)   | 8.3 (2)   | 5.8 (5)   | 0.47    |
| None                                        | 27.3 (6)  | 30.0 (12) | 8.3 (2)   | 23.3 (20) | 0.12    |
| Unsure                                      | 4.5 (1)   | 2.5 (1)   | 8.3 (2)   | 4.7 (4)   | 0.56    |
| Other                                       | 0 (0)     | 5.0 (2)   | 0 (0)     | 2.3 (2)   | 0.31    |
| **Working or in school, % (n)\(^b\)**       |           |           |           |           |         |
| Working full-/part-time                     | 31.8 (7)  | 47.5 (19) | 54.2 (13) | 45.3 (39) | 0.29    |
| Student/unemployed                          | 68.2 (15) | 52.5 (21) | 45.8 (11) | 54.7 (47) |         |
| **Gravidity**                               |           |           |           |           |         |
| Primigravid                                 | 9.1 (2)   | 15.4 (6)  | 45.8 (11) | 22.4 (19) | 0.004   |
| Median gravidity                             | 4 (2.75–5)| 2 (2–4)   | 2 (1–2.75)| 2 (2–4)   | 0.002\(^c\) |
| **Parity**                                  |           |           |           |           |         |
| Nulliparous, % (n)                          | 9.1 (2)   | 30.0 (12) | 47.8 (11) | 29.4 (25) | 0.03    |
| Median parity                               | 2 (1–2)   | 1 (0–2)   | 1 (0–1)   | 1 (0–2)   | 0.012\(^d\) |
| **Stillbirths**                             |           |           |           |           |         |
| % (n)                                       | 0 (0)     | 2.6 (1)   | 4.2 (1)   | 2.4 (2)   | 0.66    |
| Median stillbirths                           | 0 (0–0)   | 0 (0–0)   | 0 (0–0)   | 0 (0–0)   | 0.65    |
| **Adopted children**                        |           |           |           |           |         |
| % (n)                                       | 0 (0)     | 2.6 (1)   | 0 (0)     | 1.2 (1)   | 0.56    |
| Median adopted children (IQR)               | 0 (0–0)   | 0 (0–0)   | 0 (0–0)   | 0 (0–0)   | 0.57    |
| **Miscarriages**                            |           |           |           |           |         |
| % (n)                                       | 27.3 (6)  | 22.5 (9)  | 8.3 (2)   | 19.8 (17) | 0.23    |
| Median miscarriages                         | 0 (0–1)   | 0 (0–0)   | 0 (0–0)   | 0 (0–0)   | 0.26    |
| **Previous abortions**                      |           |           |           |           |         |
| % (n)                                       | 54.5 (12) | 50.0 (20) | 25.0 (6)  | 44.2 (38) | 0.08    |
| Median previous abortions                   | 1 (0–1)   | 0.5 (0–1) | 0 (0–0.75)| 0 (0–1)   | 0.15    |
| **Children in household**                   |           |           |           |           |         |
| % (n)                                       | 81.8 (18) | 72.5 (29) | 54.2 (13) | 69.8 (60) | 0.11    |
| Median children in household                | 1.5 (1–2) | 1 (0–2)   | 1 (0–1)   | 1 (0–2)   | 0.08    |

Includes participants who partially completed postprocedure survey.

\(^a\)Pearson chi square to compare proportions; Kruskal-Wallis to compare medians.

\(^b\)Respondents could select more than one response.

\(^c\)Dunn-Bonferroni adjusted pairwise comparison between 16–17.6 and 21 weeks: \(p = 0.002\).

\(^d\)Dunn-Bonferroni adjusted pairwise comparison between 16–17.6 and ≥21 weeks: \(p = 0.009\).

IQR, interquartile range.
Table 2. Reported Pain and Pain Scores at Different Moments in Abortion Process by Gestational Age (Weeks)

|                  | 16–17.6 | 18–20.6 | ≥21      | Total | p*     |
|------------------|---------|---------|----------|-------|--------|
| Cervical prep on first day | n = 16  | n = 41  | n = 23   | n = 80| 0.60   |
| Reported pain, % (n) | 81.2 (13)| 82.9 (34)| 91.3 (21)| 85.0 (68)|       |
| Median pain score scale 1–10 (IQR) | 4 (2.25–6.5) | 7 (3–8) | 5 (3–8) | 5 (3–8) | 0.29   |
| Cervical prep after going home first day | n = 21 | n = 40 | n = 24 | n = 85|        |
| Reported pain, % (n) | 61.9 (13) | 85.0 (34) | 91.7 (22) | 81.2 (69) | 0.03   |
| Median pain score scale 1–10 (IQR) | 3 (1–4) | 5 (2.25–7.75) | 3 (2–5.75) | 4 (2–6) | 0.003b |
| Cervical prep on second day | n = 9 | n = 29 | n = 21 | n = 59|        |
| Reported pain, % (n) | 77.8 (7) | 72.4 (21) | 100.0 (21) | 83.1 (49) | 0.03   |
| Median pain score scale 1–10 (IQR) | 2 (1.5–7) | 5 (1–7) | 6 (4–8.5) | 5 (2–8) | 0.05   |
| Cervical prep after going home second day | n = 8 | n = 26 | n = 18 | n = 52|        |
| Reported pain, % (n) | 62.5 (5) | 69.2 (18) | 100.0 (18) | 78.8 (41) | 0.02   |
| Median pain score scale 1–10 (IQR) | 2 (1–4) | 4 (1–6.25) | 7 (4–9) | 4 (2–7) | 0.003c |
| Digoxin administration| n = 16 | n = 40 | n = 24 | n = 79|        |
| Reported pain, % (n) | 85.0 (21) | 87.5 (21) | 87.5 (21) | N/A |        |
| Median pain score scale 1–10 (IQR) | 3 (2–5) | 3 (2–5) | N/A | N/A |        |
| Overall pain | n = 20 | n = 41 | n = 24 | n = 85|        |
| Reported pain, % (n) | 85.0 (17) | 78.0 (32) | 100.0 (24) | 85.9 (73) | 0.049  |
| Median pain score scale 1–10 (IQR) | 5 (3–7.5) | 5 (2–8) | 6 (4–8) | 5 (3–8) | 0.43   |

Data presented as % (n) unless otherwise indicated.

*pPearson chi square to compare proportions; Kruskal-Wallis to compare medians.

bDunn-Bonferroni adjusted pairwise comparison between 16–17.6 and 18–20.6 weeks: p = 0.002.

‡Dunn-Bonferroni adjusted pairwise comparison between 16–17.6 and 18–20.6 weeks: p = 0.005.

During the data cleaning process, we identified that 5 respondents in the 16- to 17.6-week group and 40 respondents in the 18- to 20.6-week group rated pain from the digoxin injection, when clinic protocol does not indicate digoxin until gestational age is 21 weeks. We recoded responses for these five participants to reflect that they did not get digoxin per clinic protocol.

21- to 23.6-week group rated their overall abortion experiences as positive or very positive, except for one person who was unsure. Only three participants rated their experiences as somewhat negative, and all were in the 18- to 20.6-week group (Table 3). More than three-fourths of respondents classified the abortion experience as better than expected, regardless of gestational age. Two people in the 18- to 20.6-week group and one person in the 21- to 23.6-week group reported that it was worse than expected (Table 3).

Shorter wait time was cited at a similar rate as the group that more frequently required three visits (Table 4).

Discussion

Our findings support that longer duration of pregnancy at the time of abortion is associated with reporting higher pain scores with the procedure. Pregnancies at later gestational ages require more cervical dilation and larger uteruses may produce stronger contractions induced by misoprostol. It is not unexpected that pain was less frequent after day 1 for respondents with 16- to 17.6-week pregnancies, especially since 11/22 people in that cohort underwent quicker cervical preparation processes and likely completed their abortion procedures in 1 day.

Although pain frequency increased with gestational age, pain intensity was similar across gestational age cohorts. Responses to the survey question about the severity of overall pain and discomfort (Fig. 2) suggested that pain was more severe than did the median pain scores, which underscores the challenges to researching, qualifying, and addressing pain, particularly since it is subjective, variable, and can be further heightened by anxiety.25–27

It is interesting to note that even though frequency of pain was higher in the 21- to 23.6-week cohort, report of a positive overall abortion experience was nonetheless common. It is not unusual in abortion studies to observe high rates of satisfaction and acceptability despite undesirable pain and side effects since participants have accessed needed care.28

It is not possible to determine from our data whether the clinic’s pain management strategies effectively reduced pain, but our findings do suggest that there is a desire for additional pain relief strategies during the abortion procedure, regardless of gestational age. There is a dearth of research on pain management...
FIG. 2. Client reported overall pain and discomfort with abortion procedure by gestational age (weeks)

- >21 weeks
- 18-20.6 weeks: p-value = 0.71; Pearson chi square to compare proportions.
- 16-17.6 weeks

FIG. 3. Client reported side effects from overall abortion experience by gestational age (weeks)

- >21 weeks
- 18-20.6 weeks
- 16-17.6 weeks

*Other: 16–17.6 not specified; 18–20.6 feeling faint, fatigue/sleepiness, pressure; >21 diarrhea and water broke. All p-values >0.05; Fisher’s exact test to compare proportions.
during later abortion—a recent review has noted that there is limited evidence on pain management strategies for abortion generally, and even a bigger lack of evidence for later abortion specifically.26

The World Health Organization (WHO),29 American College of Obstetrics and Gynecology,30 and the National Abortion Federation (NAF)31 identify various approaches to pain management, such as analgesia, anxiolytics, local anesthetic, conscious sedation, and general anesthesia, particularly after dilation is achieved, in their respective guideline, but none provides evidence-based recommendations for specific protocols especially for less resource intensive approaches, which might be preferred and are important for clinics without the infrastructure for intravenous sedation. Less complicated and more accessible pain management strategies should be prioritized for future research.

We did not find any association between side effects and gestational age, which is not necessarily unexpected. Misoprostol was used for cervical preparation in all gestational age groups and its known side effects, particularly cramping and nausea, were consistently reported. The routine use of digoxin at 18 weeks and beyond could have increased the frequency of nausea, but the group sizes are small and it is possible that additional doses of misoprostol in these later cohorts contributed to reports of nausea; we cannot separate out the effect of digoxin on nausea.

Survey respondents with pregnancies in the highest gestational age group were more likely to be pregnant for the first time and to be nulliparous compared to those in the lowest gestational age group. The published literature reflects that primary delays to care include difficulty recognizing or confirming pregnancy.32–34

Table 3. Actual Versus Expected Pain, Side Effects, and Abortion Experience by Gestational Age (Weeks)

| Pain | 16–17.6 | 18–20.6 | ≥21 | Total | p*
|------|---------|---------|-----|-------|-----|
| Pain | n=21 | n=40 | n=24 | n=85 |     |
| More than expected | 14.3 (3) | 32.5 (13) | 29.2 (7) | 27.1 (23) | 0.28 |
| Same as expected | 38.1 (8) | 20.0 (8) | 8.3 (2) | 21.2 (18) |     |
| Less than expected | 42.9 (9) | 45.0 (18) | 58.3 (14) | 48.2 (41) |     |
| Unsure | 4.8 (1) | 2.5 (1) | 4.2 (1) | 3.5 (3) |     |

| Side effects | 16–17.6 | 18–20.6 | ≥21 | Total | p*
|---------------|---------|---------|-----|-------|-----|
| Side effects | n=20 | n=40 | n=23 | n=84 |     |
| More than expected | 10.0 (2) | 27.0 (9) | 30.4 (7) | 21.4 (18) | 0.39 |
| Same as expected | 50.0 (10) | 31.7 (13) | 21.7 (5) | 33.3 (28) |     |
| Less than expected | 30.0 (6) | 34.1 (14) | 43.5 (10) | 35.7 (30) |     |
| Unsure | 10.0 (2) | 12.2 (5) | 4.3 (1) | 9.5 (8) |     |

| Abortion experience | 16–17.6 | 18–20.6 | ≥21 | Total | p*
|---------------------|---------|---------|-----|-------|-----|
| Abortion experience | n=20 | n=41 | n=23 | n=84 |     |
| Better than expected | 65.0 (13) | 82.0 (34) | 78.3 (18) | 77.4 (65) | 0.16 |
| Same as expected | 30.0 (6) | 4.9 (2) | 17.4 (4) | 14.3 (12) |     |
| Worse than expected | 0 (0) | 4.9 (2) | 4.3 (1) | 3.5 (3) |     |
| Unsure | 5.0 (1) | 7.3 (3) | 0 (0) | 4.8 (4) |     |

Data presented as % (n).
*Pearson chi square to compare proportions.

Table 4. Overall Experience of Abortion and Recommendations Regarding Pain and Number of Visits to Improve Experience by Gestational Age (Weeks)

| Abortion experience | 16–17.6 | 18–20.6 | ≥21 | Total | p*
|---------------------|---------|---------|-----|-------|-----|
| Abortion experience | n=20 | n=41 | n=23 | n=84 |     |
| Very positive | 50.0 (10) | 70.7 (29) | 75.0 (18) | 67.1 (57) | 0.12 |
| Somewhat positive | 20.0 (4) | 9.8 (4) | 20.8 (5) | 15.3 (13) |     |
| Neutral | 25.0 (5) | 9.8 (4) | 4.3 (1) | 9.5 (8) |     |
| Somewhat negative | 0 (0) | 7.3 (3) | 0 (0) | 3.5 (3) |     |
| Negative | 0 (0) | 0 (0) | 0 (0) | 0 (0) |     |
| Unsure | 5.0 (1) | 7.3 (3) | 0 (0) | 4.8 (4) |     |

| Recommendations to improve experience | 16–17.6 | 18–20.6 | ≥21 | Total | p*
|----------------------------------------|---------|---------|-----|-------|-----|
| Recommendations to improve experience | n=19 | n=37 | n=23 | n=79 |     |
| Less pain during cervical prep | 15.8 (3) | 29.7 (11) | 47.8 (11) | 31.6 (25) | 0.08 |
| Less pain during procedure | 26.3 (5) | 35.1 (13) | 17.4 (4) | 27.8 (22) | 0.32 |
| Less pain after procedure | 0 (0) | 5.4 (2) | 13.0 (3) | 6.3 (5) | 0.21 |
| Shorter wait times at clinic | 57.9 (11) | 35.1 (13) | 30.4 (7) | 39.2 (31) | 0.15 |
| Fewer visits to complete procedure | 5.3 (1) | 5.4 (2) | 17.4 (4) | 8.9 (7) | 0.23 |

Data presented as % (n).
* Pearson chi square to compare proportions.
** Fisher's exact test to compare proportions.

In our survey sample, participants in the 21- to 23.6-week group were not younger than those in the other gestational age groups even though delays in pregnancy recognition can be more acute at younger ages.33,35

Other research have reported that people with children are also more likely to take longer to get an abortion, possibly due to arranging childcare and making appointments around familial commitments;32 however, there was no statistically significant difference in the proportions of survey respondents with children when grouped by gestational age.

Our study has a few limitations. Stratifying results by cervical preparation procedure protocol was not meaningful because group sizes were so small. Another limitation is that gestational age was based on self-report and was not confirmed with clinic records. We did identify some gestational age-related inconsistencies before data cleaning, such as respondents in the earliest gestational age cohort who reported receiving digoxin when neither the original or modified cervical preparation protocols called for it, but it is unlikely that any gestational age reporting errors were widespread, as the clinic uses ultrasound to date gestational age and provides patients with the gestational age of the pregnancy before patient education.
In addition, it is possible that respondents misunderstood the lowest rating of the visual analog pain scale, where one was meant to indicate no pain and corresponded to a small circle that could have been misconstrued to represent minimal pain. Finally, statistical analyses conducted on these small group sizes cannot be generalized to the larger population.

Conclusions
In this study, people seeking abortion care at later gestations in the second trimester were more likely to report pain during their abortions. Although most respondents were prepared for the pain they experienced, some reported experiencing more pain than they expected, and more effective pain relief was commonly reported as a way to improve the service.

The findings suggest both that the clinic staff could provide more information about expected pain during counseling and that more research is needed to establish evidence-based pain management strategies, especially for cervical preparation. As pain generally increases with gestational age, future research should be powered to assess outcomes by gestational age to yield more concrete conclusions about differences in pain, side effects, and acceptability.

Authors’ Contributions
All persons who meet authorship criteria are listed as authors. L.F., K.B., and E.K. conceptualized the study; L.F. implemented the study with support from S.C., K.B., and E.K.; I.G.D. cleaned and analyzed data and drafted the article; S.C., L.F., K.B., and E.K. reviewed the article and provided feedback.

Acknowledgments
We express our gratitude to Dr. Maureen Paul for her support in reviewing our study instruments and protocol, and Ms. Susan Yanow for her support on building partnerships for this study. This study would not have been possible without the participation of Hope Clinic for Women clients as well as support from clinic staff, in particular Ms. Savannah Flanagan, who was the on-site coordinator at the time of the study, and Ms. Deborah Stopsky, who supported recruitment via the counseling staff.

Author Disclosure Statement
The authors have no conflicts of interest to declare.

Funding Information
Funding for this study was provided by the Oma Fund of the Ms. Foundation.

References
1. Jatlaoui TC, Eckhaus L, Mandel MG, et al. Abortion surveillance—United States, 2016. MMWR Surveill Summ 2019;68:1–41.
2. Lerma K, Blumenthal PD. Current and potential methods for second trimester abortion. Best Pract Res Clin Obstet Gynaecol 2020;63:24–36.
3. Peterson WF, Berry FN, Grace MR, Gubrannson CL. Second-trimester abortion by dilatation and evacuation: An analysis of 11,747 cases. Obstet Gynecol 1983;62:185–190.
4. Newmann S, Dalve-Endres A, Drey EA; Society of Family Planning. Clinical guidelines. Cervical preparation for surgical abortion from 20 to 24 weeks’ gestation. Contraception 2008;77:308–314.
5. Shaw KA, Shaw JG, Hugin M, Velasquez G, Hopkins FW, Blumenthal PD. Adjunct mifepristone for cervical preparation prior to termination of second-trimester pregnancy. Contraception 2006;73:420–430.
6. Drey EA, Benson LS, Sokoloff A, Steinauer JE, Roy G, Jackson RA. Buccal misoprostol plus laminaria for cervical preparation prior to dilatation and evacuation at 21–23 weeks of gestation: A randomized controlled trial. Contraception 2016;94:467–472.
7. Edelman AB, Buckmester JG, Goetsch MF, Nichols MD, Jensen JT. Cervical preparation using laminaria with adjunctive buccal misoprostol before second-trimester dilation and evacuation procedures: A randomized clinical trial. Am J Obstet Gynecol 2006;194:425–430.
8. Patel A, Talmont E, Morfesis J, et al. Adequacy and safety of buccal misoprostol for cervical preparation prior to termination of second-trimester pregnancy. Contraception 2006;73:420–430.
9. Drey EA, Benson LS, Sokoloff A, Steinauer JE, Roy G, Jackson RA. Buccal misoprostol plus laminaria for cervical preparation before dilatation and evacuation at 21–23 weeks of gestation: A randomized controlled trial. Contraception 2014;89:307–313.
10. Goldberg AB, Drey EA, Whitaker AK, Kang MS, Meckstroth KR, Darney PD. Misoprostol compared with laminaria before early second-trimester surgical abortion: A randomized trial. Obstet Gynecol 2005;106:234–241.
11. Goldberg AB, Fortin JA, Drey EA, et al. Cervical preparation before dilatation and evacuation using adjunctive misoprostol or mifepristone compared with overnight osmotic dilators alone: A randomized controlled trial. Obstet Gynecol 2015;126:599–609.
12. Paris AE, Sonalkar S, Kattan D, McClusky J, Vragovic O, Borgatta L. Mifepristone and misoprostol compared with osmotic dilator insertion before surgical abortion at 15–18 weeks. Obstet Gynecol 2014;123:55.
13. Borgatta L, Roncarli D, Sonalkar S, et al. Mifepristone vs. osmotic dilator insertion for cervical preparation prior to surgical abortion at 14–16 weeks: A randomized trial. Contraception 2012;86:567–571.
14. Bartz D, Maurer R, Allen RH, Fortin J, Kuan B, Goldberg AB. Buccal misoprostol compared with synthetic osmotic cervical dilator before surgical abortion: A randomized controlled trial. Obstet Gynecol 2013;122:57–63.
15. Grossman D, Constant D, Lince-Deroche N, Harries J, Kluge J. A randomized trial of misoprostol versus laminaria before dilatation and evacuation in South Africa. Contraception 2014;90:234–241.
16. Bamesh S, Roston A, Zimmerman L, Patel A, Lichtenberg ES, Chor J. Misoprostol 1 to 3 h preprocedure vs. overnight osmotic dilators prior to early second-trimester surgical abortion. Contraception 2015;92:234–240.
17. Fox MC, Krajewski CM. Cervical preparation for second-trimester surgical abortion prior to 20 weeks’ gestation. Contraception 2014;89:75–84.
18. Diedrich JT, Drey EA, Newmann SJ. Society of Family Planning clinical recommendations: Cervical preparation for dilatation and evacuation at 20–24 weeks’ gestation. Contraception 2020;101:286–292.
19. Grossman D, Constant D, Lince N, Alblas M, Blanchard K, Harries J. Surgical and medical second trimester abortion in South Africa: A cross-sectional study. BMC Health Serv Res 2011;11:224.
20. Swica Y, RagHAVAN S, Bracken H, Dabash R, Winikoff B. Review of the literature on patient satisfaction with early medical abortion using mifepristone and misoprostol. Expert Rev Obstet Gynaecol 2011;6:451–468.
21. Jackson R, Teplin V, Drey E, Thomas LJ, Darney PD. Digoxin to facilitate late second-trimester abortion: A randomized, masked, placebo-controlled trial. Obstet Gynecol 2001;97:471–476.
22. Darney BG, Powell B, Anderson K, et al. Quality of care and abortion: Beyond safety. BJM Sex Reprod Health 2018;44:159.
23. Jackson E, Kapp N. Pain management for medical and surgical termination of pregnancy between 13 and 24 weeks of gestation: A systematic review. BJOG 2020;127:1348–1357.
24. Allen RH, Singh R. Society of Family Planning clinical guidelines pain control in surgical abortion part 1—Local anesthesia and minimal sedation. Contraception 2018;97:471–477.
25. Kain ZN, Sevarino F, Alexander GM, Pincus S, Mayes LC. Preoperative anxiety and postoperative pain in women undergoing hysterectomy. A repeated-measures design. J Psychosom Res 2000;49:417–422.
26. Liu SM, Shaw KA. Pain management in outpatient surgical abortion. Curr Opin Obstet Gynecol 2021;33:440–444.
27. Bayer LL, Edelman AB, Fu R, et al. An evaluation of oral midazolam for anxiety and pain in first-trimester surgical abortion: A randomized controlled trial. Obstet Gynecol 2015;126:37–46.
28. Dennis A, Blanchard K, Bessenaar T. Identifying indicators for quality abortion care: A systematic literature review. J Fam Plann Reprod Health Care 2017;43:7.
29. World Health Organization, ed. Clinical practice handbook for safe abortion. Geneva: World Health Organization, 2014.
30. The American College of Obstetrics and Gynecology. Practice Bulletin No. 135: Second-trimester abortion. Obstet Gynecol 2013;121:1394–1406.
31. National Abortion Federation. 2020 Clinical practice guidelines for abortion care. Washington, DC: National Abortion Federation, 2020.
32. Finer LB, Frohwirth LF, Dauphinee LA, Singh S, Moore AM. Timing of steps and reasons for delays in obtaining abortions in the United States. Contraception 2006;74:334–344.
33. Jones RK, Jerman J. Characteristics and circumstances of U.S. women who obtain very early and second-trimester abortions. PLoS One 2017;12:e0169969.
34. Drey EA, Foster DG, Jackson RA, Lee SJ, Cardenas LH, Darney PD. Risk factors associated with presenting for abortion in the second trimester. Obstet Gynecol 2006;107:128–135.
35. Kiley JW, Yee LM, Niemi CM, Feinglass JM, Simon MA. Delays in request for pregnancy termination: Comparison of patients in the first and second trimesters. Contraception 2010;81:446–451.

Cite this article as: Dzuba IG, Chandrasekaran S, Fix L, Blanchard K, King E (2022) Pain, side effects, and abortion experience among people seeking abortion care in the second trimester, Women’s Health Report 3:1, 533–542, DOI: 10.1089/whr.2021.0103.

Abbreviations Used
D&E = dilation and evacuation
IQR = interquartile range

Publish in Women’s Health Reports
- Immediate, unrestricted online access
- Rigorous peer review
- Compliance with open access mandates
- Authors retain copyright
- Highly indexed
- Targeted email marketing